PDF(Pubmed)
Abstract：
BACKGROUND: Compelling evidence from preclinical and clinical studies supports the therapeutic role of cannabidiol (CBD) in several medical disorders. We reviewed the scientific evidence on CBD-related toxicity and adverse events (AEs) in 2019, at the beginning of the spike in clinical studies involving CBD. However, CBD safety remained uncertain.
OBJECTIVE: With the benefit of hindsight, we aimed to provide an update on CBD-related toxicity and AEs in humans.
METHODS: A systematic literature search was conducted following PRISMA guidelines. PubMed, Cochrane, and Embase were accessed in October 2022 to identify clinical studies mentioning CBDrelated toxicity/AEs from February 2019 to September 2022. Study design, population characteristics, CBD doses, treatment duration, co-medications, and AEs were compiled.
RESULTS: A total of 51 reports were included. Most studies investigated CBD efficacy and safety in neurological conditions, such as treatment-resistant epilepsies, although a growing number of studies are focusing on specific psychopathological conditions, such as substance use disorders, chronic psychosis, and anxiety. Most studies report mild or moderate severity of AEs. The most common AEs are diarrhea, somnolence, sedation, and upper respiratory disturbances. Few serious AEs have been reported, especially when CBD is co-administered with other classes of drugs, such as clobazam and valproate.
CONCLUSIONS: Clinical data suggest that CBD is well tolerated and associated with few serious AEs at therapeutic doses both in children and adults. However, interactions with other medications should be monitored carefully. Additional data are needed to investigate CBD\'s long-term efficacy and safety, and CBD use in medical conditions other than epilepsy syndromes.
OBJECTIVE: With the benefit of hindsight, we aimed to provide an update on CBD-related toxicity and AEs in humans.
METHODS: A systematic literature search was conducted following PRISMA guidelines. PubMed, Cochrane, and Embase were accessed in October 2022 to identify clinical studies mentioning CBDrelated toxicity/AEs from February 2019 to September 2022. Study design, population characteristics, CBD doses, treatment duration, co-medications, and AEs were compiled.
RESULTS: A total of 51 reports were included. Most studies investigated CBD efficacy and safety in neurological conditions, such as treatment-resistant epilepsies, although a growing number of studies are focusing on specific psychopathological conditions, such as substance use disorders, chronic psychosis, and anxiety. Most studies report mild or moderate severity of AEs. The most common AEs are diarrhea, somnolence, sedation, and upper respiratory disturbances. Few serious AEs have been reported, especially when CBD is co-administered with other classes of drugs, such as clobazam and valproate.
CONCLUSIONS: Clinical data suggest that CBD is well tolerated and associated with few serious AEs at therapeutic doses both in children and adults. However, interactions with other medications should be monitored carefully. Additional data are needed to investigate CBD\'s long-term efficacy and safety, and CBD use in medical conditions other than epilepsy syndromes.
摘要：
背景：来自临床前和临床研究的有力证据支持大麻二酚（CBD）在几种医学疾病中的治疗作用。我们回顾了2019年与CBD相关的毒性和不良事件（AE）的科学证据，当时涉及CBD的临床研究开始。然而,CBD的安全性仍然不确定。
目标：事后看来，我们旨在提供有关CBD相关毒性和人类不良事件的最新信息。
方法：遵循PRISMA指南进行了系统的文献检索。PubMed,科克伦,和Embase于2022年10月访问，以确定2019年2月至2022年9月提及CBD相关毒性/AE的临床研究。研究设计,人口特征，CBD剂量，治疗持续时间,联合用药,并汇编了AE。
结果：共纳入51份报告。大多数研究调查了CBD在神经系统疾病中的疗效和安全性，如抗治疗性癫痫，尽管越来越多的研究关注特定的精神病理学状况，如物质使用障碍，慢性精神病,和焦虑。大多数研究报告了轻度或中度严重的AE。最常见的不良事件是腹泻，嗜睡,镇静,和上呼吸道疾病。很少有严重的AE被报道，特别是当CBD与其他类别的药物共同施用时，如氯巴赞和丙戊酸盐。
结论：临床数据表明，儿童和成人在治疗剂量下，CBD具有良好的耐受性，并且很少发生严重的AE。然而,应监测与其他药物的相互作用。
目标：事后看来，我们旨在提供有关CBD相关毒性和人类不良事件的最新信息。
方法：遵循PRISMA指南进行了系统的文献检索。PubMed,科克伦,和Embase于2022年10月访问，以确定2019年2月至2022年9月提及CBD相关毒性/AE的临床研究。研究设计,人口特征，CBD剂量，治疗持续时间,联合用药,并汇编了AE。
结果：共纳入51份报告。大多数研究调查了CBD在神经系统疾病中的疗效和安全性，如抗治疗性癫痫，尽管越来越多的研究关注特定的精神病理学状况，如物质使用障碍，慢性精神病,和焦虑。大多数研究报告了轻度或中度严重的AE。最常见的不良事件是腹泻，嗜睡,镇静,和上呼吸道疾病。很少有严重的AE被报道，特别是当CBD与其他类别的药物共同施用时，如氯巴赞和丙戊酸盐。
结论：临床数据表明，儿童和成人在治疗剂量下，CBD具有良好的耐受性，并且很少发生严重的AE。然而,应监测与其他药物的相互作用。
